New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
10:34 EDTINSMInsmed EU update to provide near-term floor, says Piper Jaffray
Piper Jaffray attributes today's pullback in shares of Insmed to the company not immediately filing for U.S. approval of Arikayce in cystic fibrosis and nontuberculous mycobacteria. However, Piper believes the earlier than expected European filing will provide a near-term floor for shares. The firm also says the Phase 2 improvement in 6MWD in the Arikayce arm should "put to rest much of the debate over the drug's clinical utility." Piper reiterates an Overweight rating on Insmed with a $51 price target.
News For INSM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
09:01 EDTINSMInsmed 10M share Spot Secondary priced at $20.65
Subscribe for More Information
March 30, 2015
18:51 EDTINSMOn The Fly: After Hours Movers
Subscribe for More Information
16:21 EDTINSMInsmed files to sell 10M shares of common stock
Subscribe for More Information
March 24, 2015
13:54 EDTINSMInsmed personnel strong, says Piper Jaffray
After attending Insmed's analyst event, Piper says that the company has assembled a strong development and commercial team . The firm adds that the company has forged unique relationships with specialists and patients. It keeps an Overweight rating on the shares.
March 23, 2015
09:06 EDTINSMInsmed appoints Eugene Sullivan as Chief Medical and Scientific Officer
Subscribe for More Information
March 20, 2015
09:25 EDTINSMInsmed to host analyst and investor day
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use